Compare Repligen Corporation Common Stock (RGEN) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Xcel Energy Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.31B), while Xcel Energy Inc trades at $75.4 (market cap $47.07B). The key difference: Xcel Energy Inc is far larger — about 4.2× Repligen Corporation Common Stock's market cap, and Xcel Energy Inc pays a 3.14% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Xcel Energy Inc for 61 Days on average.
| RGEN | XEL | |
|---|---|---|
Market Cap | $11.31B | $47.07B |
Volume | 1,216,919 | 4,542,292 |
Sector | Health | Utilities |
52-Week High | $194.57 | $83.91 |
52-Week Low | $102.87 | $69.39 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $11.20B | $85.39B |
Dividend Yield | — | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Xcel Energy (XEL) trades at $74.64, up 0.63% with a bullish technical signal. The stock shows strong fundamentals with 2025 revenue of $14.67B and net income of $2.02B (13.75% margin). Recent earnings beat expectations in Q1 and Q2 2026, while analysts maintain a consensus buy rating with a $90.50 price target. The company benefits from rising power demand and a $60B capital expenditure plan focused on infrastructure and data center growth.
XEL offers solid growth potential driven by utility infrastructure investment and data center demand, with 62.96% analyst buy ratings supporting upside to $90.50. Key risks include wildfire liabilities, regulatory challenges, and high capital spending requirements. The stock presents a balanced opportunity for dividend-focused investors seeking regulated utility exposure with growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
